Research ArticleArticle
Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years
Denis Poddubnyy, Aleksandra Fedorova, Joachim Listing, Hildrun Haibel, Xenofon Baraliakos, Jürgen Braun and Joachim Sieper
The Journal of Rheumatology November 2016, jrheum.160594; DOI: https://doi.org/10.3899/jrheum.160594
Denis Poddubnyy
From the Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; German Rheumatism Research Centre, Berlin; Rheumazentrum Ruhrgebiet, Herne, Germany. The study with infliximab was funded by a grant from the German Ministry of Education and Research (through the Kompetenznetz Rheuma project) and by Essex Pharma/MSD Sharp and Dohme. The study with etanercept was funded by a grant from the German Ministry of Education and Research (through the Kompetenznetz Rheuma project) and by Wyeth Pharma/Pfizer Pharma. The work of AF on this project was supported by a fellowship from the Assessment of Spondyloarthritis International Society. JB received research grants, honoraria, speaker fees, and consultancy payments from Abbvie (Abbott), Novartis, and UCB. JS received research grants, honoraria, speaker fees, and/or consultancy payments from Abbvie, Janssen, Eli Lilly, MSD/Merck, Novartis, Pfizer, and UCB. D. Poddubnyy, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; A. Fedorova, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin, and Rheumazentrum Ruhrgebiet; J. Listing, PhD, German Rheumatism Research Centre; H. Haibel, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet; J. Braun, MD, Rheumazentrum Ruhrgebiet; J. Sieper, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin. Address correspondence to Prof. D. Poddubnyy, Department of Gastroenterology, Infectology and Rheumatology, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany. E-mail: denis.poddubnyy@charite.de. Accepted for publication September 29, 2016.
Aleksandra Fedorova
From the Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; German Rheumatism Research Centre, Berlin; Rheumazentrum Ruhrgebiet, Herne, Germany. The study with infliximab was funded by a grant from the German Ministry of Education and Research (through the Kompetenznetz Rheuma project) and by Essex Pharma/MSD Sharp and Dohme. The study with etanercept was funded by a grant from the German Ministry of Education and Research (through the Kompetenznetz Rheuma project) and by Wyeth Pharma/Pfizer Pharma. The work of AF on this project was supported by a fellowship from the Assessment of Spondyloarthritis International Society. JB received research grants, honoraria, speaker fees, and consultancy payments from Abbvie (Abbott), Novartis, and UCB. JS received research grants, honoraria, speaker fees, and/or consultancy payments from Abbvie, Janssen, Eli Lilly, MSD/Merck, Novartis, Pfizer, and UCB. D. Poddubnyy, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; A. Fedorova, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin, and Rheumazentrum Ruhrgebiet; J. Listing, PhD, German Rheumatism Research Centre; H. Haibel, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet; J. Braun, MD, Rheumazentrum Ruhrgebiet; J. Sieper, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin. Address correspondence to Prof. D. Poddubnyy, Department of Gastroenterology, Infectology and Rheumatology, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany. E-mail: denis.poddubnyy@charite.de. Accepted for publication September 29, 2016.
Joachim Listing
From the Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; German Rheumatism Research Centre, Berlin; Rheumazentrum Ruhrgebiet, Herne, Germany. The study with infliximab was funded by a grant from the German Ministry of Education and Research (through the Kompetenznetz Rheuma project) and by Essex Pharma/MSD Sharp and Dohme. The study with etanercept was funded by a grant from the German Ministry of Education and Research (through the Kompetenznetz Rheuma project) and by Wyeth Pharma/Pfizer Pharma. The work of AF on this project was supported by a fellowship from the Assessment of Spondyloarthritis International Society. JB received research grants, honoraria, speaker fees, and consultancy payments from Abbvie (Abbott), Novartis, and UCB. JS received research grants, honoraria, speaker fees, and/or consultancy payments from Abbvie, Janssen, Eli Lilly, MSD/Merck, Novartis, Pfizer, and UCB. D. Poddubnyy, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; A. Fedorova, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin, and Rheumazentrum Ruhrgebiet; J. Listing, PhD, German Rheumatism Research Centre; H. Haibel, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet; J. Braun, MD, Rheumazentrum Ruhrgebiet; J. Sieper, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin. Address correspondence to Prof. D. Poddubnyy, Department of Gastroenterology, Infectology and Rheumatology, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany. E-mail: denis.poddubnyy@charite.de. Accepted for publication September 29, 2016.
Hildrun Haibel
From the Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; German Rheumatism Research Centre, Berlin; Rheumazentrum Ruhrgebiet, Herne, Germany. The study with infliximab was funded by a grant from the German Ministry of Education and Research (through the Kompetenznetz Rheuma project) and by Essex Pharma/MSD Sharp and Dohme. The study with etanercept was funded by a grant from the German Ministry of Education and Research (through the Kompetenznetz Rheuma project) and by Wyeth Pharma/Pfizer Pharma. The work of AF on this project was supported by a fellowship from the Assessment of Spondyloarthritis International Society. JB received research grants, honoraria, speaker fees, and consultancy payments from Abbvie (Abbott), Novartis, and UCB. JS received research grants, honoraria, speaker fees, and/or consultancy payments from Abbvie, Janssen, Eli Lilly, MSD/Merck, Novartis, Pfizer, and UCB. D. Poddubnyy, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; A. Fedorova, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin, and Rheumazentrum Ruhrgebiet; J. Listing, PhD, German Rheumatism Research Centre; H. Haibel, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet; J. Braun, MD, Rheumazentrum Ruhrgebiet; J. Sieper, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin. Address correspondence to Prof. D. Poddubnyy, Department of Gastroenterology, Infectology and Rheumatology, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany. E-mail: denis.poddubnyy@charite.de. Accepted for publication September 29, 2016.
Xenofon Baraliakos
From the Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; German Rheumatism Research Centre, Berlin; Rheumazentrum Ruhrgebiet, Herne, Germany. The study with infliximab was funded by a grant from the German Ministry of Education and Research (through the Kompetenznetz Rheuma project) and by Essex Pharma/MSD Sharp and Dohme. The study with etanercept was funded by a grant from the German Ministry of Education and Research (through the Kompetenznetz Rheuma project) and by Wyeth Pharma/Pfizer Pharma. The work of AF on this project was supported by a fellowship from the Assessment of Spondyloarthritis International Society. JB received research grants, honoraria, speaker fees, and consultancy payments from Abbvie (Abbott), Novartis, and UCB. JS received research grants, honoraria, speaker fees, and/or consultancy payments from Abbvie, Janssen, Eli Lilly, MSD/Merck, Novartis, Pfizer, and UCB. D. Poddubnyy, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; A. Fedorova, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin, and Rheumazentrum Ruhrgebiet; J. Listing, PhD, German Rheumatism Research Centre; H. Haibel, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet; J. Braun, MD, Rheumazentrum Ruhrgebiet; J. Sieper, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin. Address correspondence to Prof. D. Poddubnyy, Department of Gastroenterology, Infectology and Rheumatology, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany. E-mail: denis.poddubnyy@charite.de. Accepted for publication September 29, 2016.
Jürgen Braun
From the Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; German Rheumatism Research Centre, Berlin; Rheumazentrum Ruhrgebiet, Herne, Germany. The study with infliximab was funded by a grant from the German Ministry of Education and Research (through the Kompetenznetz Rheuma project) and by Essex Pharma/MSD Sharp and Dohme. The study with etanercept was funded by a grant from the German Ministry of Education and Research (through the Kompetenznetz Rheuma project) and by Wyeth Pharma/Pfizer Pharma. The work of AF on this project was supported by a fellowship from the Assessment of Spondyloarthritis International Society. JB received research grants, honoraria, speaker fees, and consultancy payments from Abbvie (Abbott), Novartis, and UCB. JS received research grants, honoraria, speaker fees, and/or consultancy payments from Abbvie, Janssen, Eli Lilly, MSD/Merck, Novartis, Pfizer, and UCB. D. Poddubnyy, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; A. Fedorova, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin, and Rheumazentrum Ruhrgebiet; J. Listing, PhD, German Rheumatism Research Centre; H. Haibel, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet; J. Braun, MD, Rheumazentrum Ruhrgebiet; J. Sieper, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin. Address correspondence to Prof. D. Poddubnyy, Department of Gastroenterology, Infectology and Rheumatology, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany. E-mail: denis.poddubnyy@charite.de. Accepted for publication September 29, 2016.
Joachim Sieper
From the Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; German Rheumatism Research Centre, Berlin; Rheumazentrum Ruhrgebiet, Herne, Germany. The study with infliximab was funded by a grant from the German Ministry of Education and Research (through the Kompetenznetz Rheuma project) and by Essex Pharma/MSD Sharp and Dohme. The study with etanercept was funded by a grant from the German Ministry of Education and Research (through the Kompetenznetz Rheuma project) and by Wyeth Pharma/Pfizer Pharma. The work of AF on this project was supported by a fellowship from the Assessment of Spondyloarthritis International Society. JB received research grants, honoraria, speaker fees, and consultancy payments from Abbvie (Abbott), Novartis, and UCB. JS received research grants, honoraria, speaker fees, and/or consultancy payments from Abbvie, Janssen, Eli Lilly, MSD/Merck, Novartis, Pfizer, and UCB. D. Poddubnyy, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; A. Fedorova, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin, and Rheumazentrum Ruhrgebiet; J. Listing, PhD, German Rheumatism Research Centre; H. Haibel, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin; X. Baraliakos, MD, Rheumazentrum Ruhrgebiet; J. Braun, MD, Rheumazentrum Ruhrgebiet; J. Sieper, MD, Department of Gastroenterology, Infectology and Rheumatology, Charité Universitätsmedizin Berlin. Address correspondence to Prof. D. Poddubnyy, Department of Gastroenterology, Infectology and Rheumatology, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany. E-mail: denis.poddubnyy@charite.de. Accepted for publication September 29, 2016.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years
Denis Poddubnyy, Aleksandra Fedorova, Joachim Listing, Hildrun Haibel, Xenofon Baraliakos, Jürgen Braun, Joachim Sieper
The Journal of Rheumatology Nov 2016, jrheum.160594; DOI: 10.3899/jrheum.160594
Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years
Denis Poddubnyy, Aleksandra Fedorova, Joachim Listing, Hildrun Haibel, Xenofon Baraliakos, Jürgen Braun, Joachim Sieper
The Journal of Rheumatology Nov 2016, jrheum.160594; DOI: 10.3899/jrheum.160594